OMER logo

Omeros Corporation (OMER)

$13.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OMER

Market cap

$1.04B

EPS

1.73

P/E ratio

13

Price to sales

37.36

Dividend yield

--

Beta

2.968753

Price on OMER

Previous close

$16.68

Today's open

$14.34

Day's range

$12.70 - $14.65

52 week range

$6.70 - $21.24

Profile about OMER

CEO

Gregory A. Demopulos

Employees

175

Headquarters

Seattle, WA

Exchange

NASDAQ Global Market

Shares outstanding

74463571

Issue type

Common Stock

OMER industries and sectors

Healthcare

Biotechnology & Life Sciences

News on OMER

Omeros: Yartemlea Commercial Momentum Supports Upgrade Despite Q3 Deceleration (Rating Upgrade)

Omeros earns a speculative buy upgrade: YARTEMLEA's stronger-than-expected launch supports a valuation floor, while zaltenibart and the pipeline offer upside. Q3 net product revenue rose 26% sequentially to $35.9 million, but growth decelerated sharply, and elevated expectations leave little room for disappointment. My revised U.S. model values YARTEMLEA at $870.6 million, with up to $350 million in peak annual sales; OMER's enterprise value is near $1 billion.

news source

Seeking Alpha • 21 hours ago

news preview

Omeros Q3 Earnings Call Highlights

Omeros NASDAQ: OMER reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss.

news source

MarketBeat • Nov 17, 2026

news preview

Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript

Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Omeros Corporation Reports Third Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include: Third Quarter and Recent Highlights YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third qua.

news source

Business Wire • Nov 16, 2026

news preview

Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates

Omeros (OMER) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.19 per share a year ago.

news source

Zacks Investment Research • Nov 16, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please c.

news source

Business Wire • Nov 10, 2026

news preview

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.

news source

Benzinga • Oct 16, 2026

news preview

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.

news source

Business Wire • Oct 16, 2026

news preview

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.

news source

Benzinga • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Omeros Corporation

Open an M1 investment account to buy and sell Omeros Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OMER on M1